Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Molecular Staging for Survival Prediction of Colorectal Cancer Patients

Open access
Eschrich, Steven, Yang, Ivana, Bloom, Greg, Kwong, Ka Yin, Boulware, David, Cantor, Alan, Coppola, Domenico, Kruhøffer, Mogens, Aaltonen, Lauri, Orntoft, Torben F., Quackenbush, John, Yeatman, Timothy J. · 2005 · Journal of Clinical Oncology

Abstract

Purpose: The Dukes' staging system is the gold standard for predicting colorectal cancer prognosis; however, accurate classification of intermediate-stage cases is problematic. We hypothesized that molecular fingerprints could provide more accurate staging and potentially assist in directing adjuvant therapy. Methods: A 32,000 cDNA microarray was used to evaluate 78 human colon cancer specimens, and these results were correlated with survival. Molecular classifiers were produced to predict outcome. Results: Molecular staging, based on 43 core genes, was 90% accurate (93% sensitivity, 84% specificity) in predicting 36-month overall survival in 78 patients. This result was significantly better than Dukes' staging (P = .03878), discriminated patients into significantly different groups by survival time (P < .001, log-rank test), and was significantly different from chance (P < .001, 1,000 permutations). Furthermore, the classifier was able to discriminate a survival difference in an independent test set from Denmark. Molecular staging identifies patient prognosis (as represented by 36-month survival) more accurately than the traditional clinical staging, particularly for intermediate Dukes' stage B and C patients. The classifier was based on a core set of 43 genes, including osteopontin and neuregulin, which have biologic significance for this disease. Conclusion: These data support further evaluation of molecular staging to discriminate good from poor prognosis patients, with the potential to direct adjuvant therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.00.695

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 348

Metadata

Authors
Eschrich, S., Yang, I., Bloom, G., Kwong, K. Y., Boulware, D., Cantor, A., Coppola, D., Kruhøffer, M., Aaltonen, L., Orntoft, T. F., Quackenbush, J., & Yeatman, T. J.
Venue
Journal of Clinical Oncology
Published
2005-05-20
Volume
23
Issue
15
Pages
3526-3535
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2114739452
Cited by
348
References
22
FWCI
11.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Staging for Survival Prediction of Colorectal Cancer Patients. https://app.cochat.ai/papers/10.1200/jco.2005.00.695
The paper
Eschrich, S., Yang, I., Bloom, G., Kwong, K. Y., Boulware, D., Cantor, A., Coppola, D., Kruhøffer, M., Aaltonen, L., Orntoft, T. F., Quackenbush, J., & Yeatman, T. J. (2005). Molecular Staging for Survival Prediction of Colorectal Cancer Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.00.695

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.